Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Steven Gilman Insider Profile
4 Followers
Steven Gilman, EVP & Chief Scientific Officer at Cubist Pharma, holds 0.00 shares in Momenta Pharma (Ticker: MNTA), holds 38.86K shares in Akebia Therapeutics (Ticker: AKBA), holds 1.75K shares in Vericel (Ticker: VCEL).
Steven Gilman Cubist Pharma (CBST)EVP & Chief Scientific Officer
Cubist Pharma (CBST)
EVP & Chief Scientific Officer
Ranked #43,616 out of 78,624 Corporate Insiders
Profitable Transactions
1 out of 4 Profitable Transactions
Average Return
-3.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Steven Gilman holds in companies
Most Profitable Insider Trade
The most profitable trade made by Steven Gilman
Steven Gilman's Trading History
Cubist Pharma
Jan 21, 2015
―
Uninformative Sell
3.11M
―
Keryx Biopharma
Dec 13, 2018
―
Uninformative Sell
―
$0.00
Momenta Pharma
Oct 01, 2020
―
Uninformative Sell
―
$0.00
Akebia Therapeutics
Jun 09, 2020
Director
Uninformative Buy
―
$131.75K
Vericel
May 01, 2020
Director
Uninformative Buy
―
$44.10K
ContraFect
Jul 26, 2017
Director
Informative Buy
992.00
$0.00
SCYNEXIS
―
Director
―
$0.00
List of latest transactions for each holding click on a transaction to see Steven Gilman's performance on stock
You May Also Like
Steven Gilman insider profile FAQ
What is the percentage of profitable transactions made by Steven Gilman?
The percentage of profitable transactions made by Steven Gilman is 25%.
What is the average return per transaction made by Steven Gilman?
The average return per transaction made by Steven Gilman is -3.40%.
What stocks does Steven Gilman hold?
Steven Gilman holds: CBST, KERX, MNTA, AKBA, VCEL, CFRX, SCYX stocks.
What was Steven Gilman’s latest transaction?
Steven Gilman latest transaction was an Uninformative Sell of ―.
What was Steven Gilman's most profitable transaction?
Steven Gilman’s most profitable transaction was an Informative Buy of CFRX stock on July 26, 2017. The return on the trade was 75.20%.
What is Steven Gilman's role in Cubist Pharma?
Steven Gilman's role in Cubist Pharma is EVP & Chief Scientific Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.